Evaluation for Transplant
CCI Impacts Survival
Patient Characteristics -- MDS
HSCT for AML and MDS By Age: TRM and Relapse
Overall Survival: HSCT for MDS By Age
Conditioning Regimens
Pharmacokinetics: Goal of Therapy
Implications of Altered Drug Distribution of Bu
Improving Outcomes
Response to Azacitidine: IWG Criteria ITT Cohort (n = 282)
New Cytogenetic Scoring System in MDS
Survival by 5-group Cytogenetic Classification
Azacitidine After Allo-SCT
3-Year OS Based On Pretransplantation Treatment
Case 2: Myeloma Transformed into AML
Life Expectancy at Age 65 Years and 85 Years by Gender
Impact of Charlson Comorbidity Index
2-year NRM Stratified by HCTCI Scores
Functional Assessment
Case 3: CML (cont)
Multivariate Analysis: DFS
Conditioning Regimens
Mutation-Dependent Maintenance Therapy
Abbreviations (cont)
Abbreviations (cont)
Abbreviations (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)